UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings

PloS one, 2017-05, Vol.12 (5), p.e0174463-e0174463

2017

Volltextzugriff (PDF)

Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score

Frontiers in pharmacology, 2022-06, Vol.13, p.877118

2022

Volltextzugriff (PDF)

Antigen specificity and cross-reactivity drive functionally diverse anti-Aspergillus fumigatus T cell responses in cystic fibrosis

The Journal of clinical investigation, 2023-03, Vol.133 (5)

2023

Volltextzugriff (PDF)

Elevated Levels of Toxic Bile Acids in Serum of Cystic Fibrosis Patients with CFTR Mutations Causing Pancreatic Insufficiency

International journal of molecular sciences, 2022-10, Vol.23 (20), p.12436

2022

Volltextzugriff (PDF)

Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining Fluid

Frontiers in immunology, 2021-05, Vol.12, p.642180-642180

2021

Volltextzugriff (PDF)

Proliferative activity of antigen-specific CD154+ T cells against bacterial and fungal respiratory pathogens in cystic fibrosis decreases after initiation of highly effective CFTR modulator therapy

Frontiers in pharmacology, 2023-06, Vol.14, p.1180826-1180826

2023

Volltextzugriff (PDF)

The burden of sinus disease in cystic fibrosis lung transplant recipients

Transplant infectious disease, 2018-10, Vol.20 (5), p.e12924-n/a

2018

Volltextzugriff (PDF)

Divergent dynamics of inflammatory mediators and multiplex PCRs during airway infection in cystic fibrosis patients and healthy controls: Serial upper airway sampling by nasal lavage

Frontiers in immunology, 2022-11, Vol.13, p.947359

2022

Volltextzugriff (PDF)

Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms

Nutrients, 2020-04, Vol.12 (4), p.1014

2020

Volltextzugriff (PDF)

Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis - where do we stand?

Expert opinion on drug delivery, 2015-08, Vol.12 (8), p.1351-1374

2015

Volltextzugriff (PDF)

Reduced nasal nitric oxide production in cystic fibrosis patients with elevated systemic inflammation markers

PloS one, 2013-11, Vol.8 (11), p.e79141-e79141

2013

Volltextzugriff (PDF)

Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score

Frontiers in pharmacology, 2023-05, Vol.14, p.1207356-1207356

2023

Volltextzugriff (PDF)

Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire

Frontiers in pharmacology, 2023-10, Vol.14, p.1167407-1167407

2023

Volltextzugriff (PDF)

32. Jahrestagung der Arbeitsgemeinschaft für Pädiatrische Pneumologie und Allergologie (APPA) e. V.; 20. – 21. Oktober 2023, Brandenburg an der Havel

Allergologie, 2023-10, Vol.46 (10), p.701-714

Mainz, Jochen G.

2023

Volltextzugriff (PDF)

Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores

PloS one, 2012-07, Vol.7 (7), p.e42139

2012

Volltextzugriff (PDF)

Prevalence of constipation in cystic fibrosis patients: a systematic review of observational studies

Jornal de pediatria, 2020-11, Vol.96 (6), p.686-692

2020

Volltextzugriff (PDF)

Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy

BMJ open respiratory research, 2024-05, Vol.11 (1), p.e002049

2024

Volltextzugriff (PDF)

Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study

BMC pulmonary medicine, 2019-08, Vol.19 (1), p.146-146, Article 146

2019

Volltextzugriff (PDF)

Would it have happened without Christmas? Thoracic emphysema and allergic bronchopulmonary aspergillosis in a juvenile cystic fibrosis patient with the G551D mutation receiving ivacaftor

ERJ open research, 2021-04, Vol.7 (2), p.758

2021

Volltextzugriff (PDF)

Therapy of CF-Patients with Amitriptyline and Placebo - a Randomised, Double-Blind, Placebo-Controlled Phase IIb Multicenter, Cohort-Study

Cellular physiology and biochemistry, 2013-01, Vol.31 (4-5), p.505-512

2013

Volltextzugriff (PDF)

Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation

American journal of respiratory and critical care medicine, 2013-06, Vol.187 (11), p.1219-1225

2013

Volltextzugriff (PDF)

Abdominal Symptoms Assessed With the CFAbd‐Score are Associated With Intestinal Inflammation in Patients With Cystic Fibrosis

Journal of pediatric gastroenterology and nutrition, 2022-03, Vol.74 (3), p.355-360

2022

Volltextzugriff (PDF)

Chronic rhinosinusitis in people with CF, a rapidly changing field

Journal of cystic fibrosis, 2024-03, Vol.23 (2), p.183-184

2024

Volltextzugriff (PDF)

Adherence to therapies in cystic fibrosis: a targeted literature review

Expert review of respiratory medicine, 2017-02, Vol.11 (2), p.129-145

2017

Volltextzugriff (PDF)

1 – 25 von 89

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(85)
Mit Volltextzugriff
(75)

Publikationsform

Artikel
(88)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings

Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score

Antigen specificity and cross-reactivity drive functionally diverse anti-Aspergillus fumigatus T cell responses in cystic fibrosis

Factors Associated with Worse Lung Function in Cystic Fibrosis Patients with Persistent Staphylococcus aureus

Elevated Levels of Toxic Bile Acids in Serum of Cystic Fibrosis Patients with CFTR Mutations Causing Pancreatic Insufficiency

Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining Fluid

Proliferative activity of antigen-specific CD154+ T cells against bacterial and fungal respiratory pathogens in cystic fibrosis decreases after initiation of highly effective CFTR modulator therapy

The burden of sinus disease in cystic fibrosis lung transplant recipients

Divergent dynamics of inflammatory mediators and multiplex PCRs during airway infection in cystic fibrosis patients and healthy controls: Serial upper airway sampling by nasal lavage

Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms

Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis - where do we stand?

Reduced nasal nitric oxide production in cystic fibrosis patients with elevated systemic inflammation markers

Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score

Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire

32. Jahrestagung der Arbeitsgemeinschaft für Pädiatrische Pneumologie und Allergologie (APPA) e. V.; 20. – 21. Oktober 2023, Brandenburg an der Havel

Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores

Prevalence of constipation in cystic fibrosis patients: a systematic review of observational studies

Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy

Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study

Would it have happened without Christmas? Thoracic emphysema and allergic bronchopulmonary aspergillosis in a juvenile cystic fibrosis patient with the G551D mutation receiving ivacaftor

Therapy of CF-Patients with Amitriptyline and Placebo - a Randomised, Double-Blind, Placebo-Controlled Phase IIb Multicenter, Cohort-Study

Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation

Abdominal Symptoms Assessed With the CFAbd‐Score are Associated With Intestinal Inflammation in Patients With Cystic Fibrosis

Chronic rhinosinusitis in people with CF, a rapidly changing field

Adherence to therapies in cystic fibrosis: a targeted literature review

Suchergebnisse filtern